PMID- 31324163 OWN - NLM STAT- MEDLINE DCOM- 20191231 LR - 20200225 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 19 IP - 1 DP - 2019 Jul 19 TI - Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China. PG - 717 LID - 10.1186/s12885-019-5877-9 [doi] LID - 717 AB - BACKGROUND: Ependymal tumors are pathologically defined intrinsic neoplasms originating in the intracranial compartments or the spinal cord that affect both children and adults. The recently integrated classification of ependymomas based on both histological and molecular characteristics is capable of subgrouping patients with various prognoses. However, the application of histological and molecular markers in Chinese patients with ependymomas has rarely been reported. We aimed to demonstrate the significance of histological characteristics, the v-relavian reticuloendotheliosis viral oncogene homolog A (RELA) fusions and other molecular features in ependymal tumors. METHODS: We reviewed the histological characteristics of ependymal tumors using conventional pathological slides and investigate the RELA fusions and Cylclin D1 (CCND1) amplification by Fluorescence in situ hybridization (FISH) and trimethylation of histone 3 lysine 27 (H3K27me3) expression by immunohistochemistry (IHC) methods. SPSS software was used to analyze the data. RESULTS: We demonstrated that hypercellularity, atypia, microvascular proliferation, necrosis, mitosis, and an elevated Ki-67 index, were tightly associated with an advanced tumor grade. Tumor location, necrosis, mitosis and the Ki-67 index were related to the survival of the ependymomas, but Ki67 was the only independent prognostic factor. Additionally, RELA fusions, mostly presented in pediatric grade III intracranial ependymomas, indicated decreased survival times of patients, and closely related to the patients' age, tumor grade, cellularity, cellular atypia, necrosis and Ki67 index in the intracranial ependymal tumors, whereas reduction of H3K27me3 predicted the worse prognosis in ependymal tumors. CONCLUSIONS: Histological and molecular features facilitate tumor grading and prognostic predictions for ependymal tumors in Chinese patients. FAU - Xi, Shaoyan AU - Xi S AD - Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. FAU - Sai, Ke AU - Sai K AD - Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Rd. East, Guangzhou, 510060, China. FAU - Hu, Wanming AU - Hu W AD - Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. FAU - Wang, Fang AU - Wang F AD - Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. FAU - Chen, Yinsheng AU - Chen Y AD - Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Rd. East, Guangzhou, 510060, China. FAU - Wang, Jing AU - Wang J AD - Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Rd. East, Guangzhou, 510060, China. FAU - Zeng, Jing AU - Zeng J AD - Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. zengjing@sysucc.org.cn. FAU - Chen, Zhongping AU - Chen Z AD - Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Rd. East, Guangzhou, 510060, China. chenzhp@sysucc.org.cn. LA - eng GR - 81372685/National Natural Science Funds of China/ GR - 81872059/National Natural Science Funds of China/ GR - 81572479/National Natural Science Funds of China/ GR - 81772677/National Natural Science Funds of China/ GR - 81772675/National Natural Science Funds of China/ GR - 2015CB755505/National Basic Research Program of China (973)/ GR - 2012AA02A508/National High Technology Research and Development Program of China (863)/ GR - 201508020125/Guangzhou Science Technology and Innovation Project/ GR - 2016A020213004/Science and Technology Planning Project/ GR - S2013040012894/Natural Science Funds of Guangdong Province/ GR - 2016A030313309/Natural Science Foundation of Guangdong Province/ PT - Journal Article DEP - 20190719 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (CCND1 protein, human) RN - 0 (Histones) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (RELA protein, human) RN - 0 (Transcription Factor RelA) RN - 0 (histone H3 trimethyl Lys4) RN - 136601-57-5 (Cyclin D1) SB - IM MH - Adolescent MH - Adult MH - Biomarkers, Tumor/analysis MH - Brain Neoplasms/*pathology/surgery MH - Child MH - China MH - Cyclin D1/analysis MH - Ependymoma/*pathology/surgery MH - Female MH - Follow-Up Studies MH - Histones/*analysis MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/*analysis MH - Male MH - Necrosis MH - Neoplasm Grading MH - Prognosis MH - Spinal Cord Neoplasms/*pathology/surgery MH - Transcription Factor RelA/*analysis MH - Young Adult PMC - PMC6642607 OTO - NOTNLM OT - Ependymal tumor OT - H3K27me3 OT - Histological characteristics OT - Prognosis OT - RELA COIS- The authors declare that they have no competing interests. EDAT- 2019/07/22 06:00 MHDA- 2020/01/01 06:00 PMCR- 2019/07/19 CRDT- 2019/07/21 06:00 PHST- 2019/01/06 00:00 [received] PHST- 2019/06/24 00:00 [accepted] PHST- 2019/07/21 06:00 [entrez] PHST- 2019/07/22 06:00 [pubmed] PHST- 2020/01/01 06:00 [medline] PHST- 2019/07/19 00:00 [pmc-release] AID - 10.1186/s12885-019-5877-9 [pii] AID - 5877 [pii] AID - 10.1186/s12885-019-5877-9 [doi] PST - epublish SO - BMC Cancer. 2019 Jul 19;19(1):717. doi: 10.1186/s12885-019-5877-9.